Distribution and functional significance of somatostatin receptors in malignant melanoma

Sharon S. Lum, William S. Fletcher, M. Sue O'Dorisio, Robert Nance, Rodney Pommier, Moonkung Caprara

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Malignant melanoma is a neuroendocrine tumor that contains somatostatin receptors (SSTRs). Adjuvant therapy for melanoma is limited. Because melanomas arise from neural crest cells, we sought to evaluate the distribution of SSTR subtypes found in these tumors and their functional significance by imaging with 111In-pentetreotide scintigraphy (OctreoScan). Octreotide binds with greatest affinity to SSTR2 and SSTR5. Studying the expression of SSTRs in melanoma may demonstrate a potential role for octreotide in the treatment of melanoma. A series of 23 melanomas from 17 patients who underwent resection of regional or distant metastases were evaluated for the presence of SSTRs by the reverse transcriptase-polymerase chain reaction (RT-PCR) using primers specific for SSTR1 through SSTR5. Identity of RT-PCR products was confirmed by Southern blot analysis. Sixteen patients underwent preoperative OctreoScan. SSTR1 was expressed in 96% of tumors, SSTR2 in 83%, SSTR3 in 61%, SSTR4 in 57%, and SSTR5 in 9%. OctreoScan imaged 63% of tumors. There was no correlation between SSTR subtype expression and OctreoScan result. Most of the melanomas expressed mRNA for SSTR1 and SSTR2, with approximately half expressing SSTR3 and SSTR4. The SSTR mRNA for SSTR2 appears to be transcribed into functional protein that binds 111In-pentetreotide in more than half of these patients. Although OctreoScan has limited sensitivity for localizing melanomas, tumors that can be imaged by OctreoScan may be amenable to adjuvant therapy with octreotide or targeted therapy with high-energy radioisotope-labeled octreotide. These studies clearly define melanoma as a neuroendocrine tumor, which may open new avenues for tumor control.

Original languageEnglish (US)
Pages (from-to)407-412
Number of pages6
JournalWorld Journal of Surgery
Volume25
Issue number4
DOIs
StatePublished - Apr 2001

Fingerprint

Somatostatin Receptors
Melanoma
Octreotide
Neuroendocrine Tumors
Neoplasms
Reverse Transcriptase Polymerase Chain Reaction
Messenger RNA
pentetreotide
Neural Crest
Therapeutics
Southern Blotting
Radioisotopes
Radionuclide Imaging
Neoplasm Metastasis

ASJC Scopus subject areas

  • Surgery

Cite this

Distribution and functional significance of somatostatin receptors in malignant melanoma. / Lum, Sharon S.; Fletcher, William S.; O'Dorisio, M. Sue; Nance, Robert; Pommier, Rodney; Caprara, Moonkung.

In: World Journal of Surgery, Vol. 25, No. 4, 04.2001, p. 407-412.

Research output: Contribution to journalArticle

Lum, Sharon S. ; Fletcher, William S. ; O'Dorisio, M. Sue ; Nance, Robert ; Pommier, Rodney ; Caprara, Moonkung. / Distribution and functional significance of somatostatin receptors in malignant melanoma. In: World Journal of Surgery. 2001 ; Vol. 25, No. 4. pp. 407-412.
@article{41b5f8e61fbc4ab6bd1ec29286c9a78b,
title = "Distribution and functional significance of somatostatin receptors in malignant melanoma",
abstract = "Malignant melanoma is a neuroendocrine tumor that contains somatostatin receptors (SSTRs). Adjuvant therapy for melanoma is limited. Because melanomas arise from neural crest cells, we sought to evaluate the distribution of SSTR subtypes found in these tumors and their functional significance by imaging with 111In-pentetreotide scintigraphy (OctreoScan). Octreotide binds with greatest affinity to SSTR2 and SSTR5. Studying the expression of SSTRs in melanoma may demonstrate a potential role for octreotide in the treatment of melanoma. A series of 23 melanomas from 17 patients who underwent resection of regional or distant metastases were evaluated for the presence of SSTRs by the reverse transcriptase-polymerase chain reaction (RT-PCR) using primers specific for SSTR1 through SSTR5. Identity of RT-PCR products was confirmed by Southern blot analysis. Sixteen patients underwent preoperative OctreoScan. SSTR1 was expressed in 96{\%} of tumors, SSTR2 in 83{\%}, SSTR3 in 61{\%}, SSTR4 in 57{\%}, and SSTR5 in 9{\%}. OctreoScan imaged 63{\%} of tumors. There was no correlation between SSTR subtype expression and OctreoScan result. Most of the melanomas expressed mRNA for SSTR1 and SSTR2, with approximately half expressing SSTR3 and SSTR4. The SSTR mRNA for SSTR2 appears to be transcribed into functional protein that binds 111In-pentetreotide in more than half of these patients. Although OctreoScan has limited sensitivity for localizing melanomas, tumors that can be imaged by OctreoScan may be amenable to adjuvant therapy with octreotide or targeted therapy with high-energy radioisotope-labeled octreotide. These studies clearly define melanoma as a neuroendocrine tumor, which may open new avenues for tumor control.",
author = "Lum, {Sharon S.} and Fletcher, {William S.} and O'Dorisio, {M. Sue} and Robert Nance and Rodney Pommier and Moonkung Caprara",
year = "2001",
month = "4",
doi = "10.1007/s002680020102",
language = "English (US)",
volume = "25",
pages = "407--412",
journal = "World Journal of Surgery",
issn = "0364-2313",
publisher = "Springer New York",
number = "4",

}

TY - JOUR

T1 - Distribution and functional significance of somatostatin receptors in malignant melanoma

AU - Lum, Sharon S.

AU - Fletcher, William S.

AU - O'Dorisio, M. Sue

AU - Nance, Robert

AU - Pommier, Rodney

AU - Caprara, Moonkung

PY - 2001/4

Y1 - 2001/4

N2 - Malignant melanoma is a neuroendocrine tumor that contains somatostatin receptors (SSTRs). Adjuvant therapy for melanoma is limited. Because melanomas arise from neural crest cells, we sought to evaluate the distribution of SSTR subtypes found in these tumors and their functional significance by imaging with 111In-pentetreotide scintigraphy (OctreoScan). Octreotide binds with greatest affinity to SSTR2 and SSTR5. Studying the expression of SSTRs in melanoma may demonstrate a potential role for octreotide in the treatment of melanoma. A series of 23 melanomas from 17 patients who underwent resection of regional or distant metastases were evaluated for the presence of SSTRs by the reverse transcriptase-polymerase chain reaction (RT-PCR) using primers specific for SSTR1 through SSTR5. Identity of RT-PCR products was confirmed by Southern blot analysis. Sixteen patients underwent preoperative OctreoScan. SSTR1 was expressed in 96% of tumors, SSTR2 in 83%, SSTR3 in 61%, SSTR4 in 57%, and SSTR5 in 9%. OctreoScan imaged 63% of tumors. There was no correlation between SSTR subtype expression and OctreoScan result. Most of the melanomas expressed mRNA for SSTR1 and SSTR2, with approximately half expressing SSTR3 and SSTR4. The SSTR mRNA for SSTR2 appears to be transcribed into functional protein that binds 111In-pentetreotide in more than half of these patients. Although OctreoScan has limited sensitivity for localizing melanomas, tumors that can be imaged by OctreoScan may be amenable to adjuvant therapy with octreotide or targeted therapy with high-energy radioisotope-labeled octreotide. These studies clearly define melanoma as a neuroendocrine tumor, which may open new avenues for tumor control.

AB - Malignant melanoma is a neuroendocrine tumor that contains somatostatin receptors (SSTRs). Adjuvant therapy for melanoma is limited. Because melanomas arise from neural crest cells, we sought to evaluate the distribution of SSTR subtypes found in these tumors and their functional significance by imaging with 111In-pentetreotide scintigraphy (OctreoScan). Octreotide binds with greatest affinity to SSTR2 and SSTR5. Studying the expression of SSTRs in melanoma may demonstrate a potential role for octreotide in the treatment of melanoma. A series of 23 melanomas from 17 patients who underwent resection of regional or distant metastases were evaluated for the presence of SSTRs by the reverse transcriptase-polymerase chain reaction (RT-PCR) using primers specific for SSTR1 through SSTR5. Identity of RT-PCR products was confirmed by Southern blot analysis. Sixteen patients underwent preoperative OctreoScan. SSTR1 was expressed in 96% of tumors, SSTR2 in 83%, SSTR3 in 61%, SSTR4 in 57%, and SSTR5 in 9%. OctreoScan imaged 63% of tumors. There was no correlation between SSTR subtype expression and OctreoScan result. Most of the melanomas expressed mRNA for SSTR1 and SSTR2, with approximately half expressing SSTR3 and SSTR4. The SSTR mRNA for SSTR2 appears to be transcribed into functional protein that binds 111In-pentetreotide in more than half of these patients. Although OctreoScan has limited sensitivity for localizing melanomas, tumors that can be imaged by OctreoScan may be amenable to adjuvant therapy with octreotide or targeted therapy with high-energy radioisotope-labeled octreotide. These studies clearly define melanoma as a neuroendocrine tumor, which may open new avenues for tumor control.

UR - http://www.scopus.com/inward/record.url?scp=0035023109&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035023109&partnerID=8YFLogxK

U2 - 10.1007/s002680020102

DO - 10.1007/s002680020102

M3 - Article

C2 - 11344389

AN - SCOPUS:0035023109

VL - 25

SP - 407

EP - 412

JO - World Journal of Surgery

JF - World Journal of Surgery

SN - 0364-2313

IS - 4

ER -